Citation

  • Authors: Xu, K., Ding, Q., Fang, Z., Zheng, J., Gao, P., Lu, Y., Zhang, Y.
  • Year: 2010
  • Journal: Cancer Gene Ther 17 212-22
  • Applications: in vivo / shRNA plasmid / in vivo-jetPEI

Method

Wild-type Caki-1 and OS-RC-2 cells were injected s.c. into nude mice. After 5 days, mice received intratumoral injections (20 µg shRNA encoding plasmid per injection in 3 sites per tumor) of in vivo-jetPEI/ HIF-1asi twice weekly for 32 days. Tumor size was measured throughout.

Abstract

Hypoxia-inducible factor-1alpha (HIF-1alpha) is a main responder to intracellular hypoxia and is overexpressed in many human cancers, including renal cell carcinoma (RCC). To better understanding of the role of HIF-1alpha in the tumorigenicity of RCC, we used short-hairpin RNA (shRNA) interference to inhibit HIF-1alpha expression in the human renal cancer cell line, Caki-1 and OS-RC-2. Silencing of HIF-1alpha significantly reduced the expression of HIF-1alpha in both of renal cancer cell lines. In vitro downregulation of HIF-1alpha inhibited Caki-1 and OS-RC-2 cell growth, migration and invasion. The results further showed that HIF-1alpha silencing resulted in caspase-dependent apoptosis of Caki-1 and OS-RC-2 through regulation of PI3K/Akt pathway and Bcl-2-related proteins expression. In vivo animal studies showed that tumor growth was significantly inhibited in HIF-1alpha shRNA-transfected RCC. Intratumor gene therapy with polyethylenimine-loaded HIF-1alpha shRNA also resulted in tumor growth suppression. Thus, this study demonstrates that downregulation of HIF-1alpha could suppress tumorigenicity of RCC through induction of apoptosis, and HIF-1alpha shRNA may be a promising strategy for the treatment of RCC.

Go to